Cargando…

Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His

Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shteinberg, Michal, Downey, Damian G., Beattie, Diane, McCaughan, John, Reid, Alastair, Stein, Nili, Elborn, J. Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566269/
https://www.ncbi.nlm.nih.gov/pubmed/28845426
http://dx.doi.org/10.1183/23120541.00056-2016
_version_ 1783258521696993280
author Shteinberg, Michal
Downey, Damian G.
Beattie, Diane
McCaughan, John
Reid, Alastair
Stein, Nili
Elborn, J. Stuart
author_facet Shteinberg, Michal
Downey, Damian G.
Beattie, Diane
McCaughan, John
Reid, Alastair
Stein, Nili
Elborn, J. Stuart
author_sort Shteinberg, Michal
collection PubMed
description Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lung disease of CF patients carrying the p.Arg117His mutation with different intron 9 varying sequences (poly-T) and mutation classes in trans. Data were collected from patients in Northern Ireland, UK, including diagnostic features, sweat chloride, nutritional status, sputum microbiology, CF-related complications and lung function. Poly-T and TG repeats were determined by PCR. Forced expiratory volume in 1 s (FEV(1)) decline was determined from linear regression of FEV(1) measurements of patients over time. We identified 62 patients with p.Arg117His, 55 with a class I/II mutation in trans and six with p.Arg117His/p.Gly551Asp. 42 patients had 5T and 13 had 7T. All patients had 12 TG repeats. Patients with p.Arg117His-5T had greater lung function decline, sweat chloride concentrations, pancreatic insufficiency and prevalence of Pseudomonas aeruginosa infection compared with patients with p.Arg117His-7T. Lung function decline and disease severity in p.Arg117His is determined by the poly-T tract length and identity of the mutation in trans. Patients with p.Arg117His-5T and a second class I/II mutation have a severity similar to p.Phe508del homozygous patients, although lung function decline is delayed to an older age. There may be linkage disequilibrium between p.Arg117His and 12 TG repeats.
format Online
Article
Text
id pubmed-5566269
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Respiratory Society
record_format MEDLINE/PubMed
spelling pubmed-55662692017-08-25 Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His Shteinberg, Michal Downey, Damian G. Beattie, Diane McCaughan, John Reid, Alastair Stein, Nili Elborn, J. Stuart ERJ Open Res Original Articles Expression of p.Arg117His cystic fibrosis (CF) transmembrane conductance regulator is influenced by a polythymidine (poly-T) tract and a thymidine–guanine (TG) repeat on intron 9, which vary in length and affect exon 10 skipping. We compared clinical characteristics and the rate of progression of lung disease of CF patients carrying the p.Arg117His mutation with different intron 9 varying sequences (poly-T) and mutation classes in trans. Data were collected from patients in Northern Ireland, UK, including diagnostic features, sweat chloride, nutritional status, sputum microbiology, CF-related complications and lung function. Poly-T and TG repeats were determined by PCR. Forced expiratory volume in 1 s (FEV(1)) decline was determined from linear regression of FEV(1) measurements of patients over time. We identified 62 patients with p.Arg117His, 55 with a class I/II mutation in trans and six with p.Arg117His/p.Gly551Asp. 42 patients had 5T and 13 had 7T. All patients had 12 TG repeats. Patients with p.Arg117His-5T had greater lung function decline, sweat chloride concentrations, pancreatic insufficiency and prevalence of Pseudomonas aeruginosa infection compared with patients with p.Arg117His-7T. Lung function decline and disease severity in p.Arg117His is determined by the poly-T tract length and identity of the mutation in trans. Patients with p.Arg117His-5T and a second class I/II mutation have a severity similar to p.Phe508del homozygous patients, although lung function decline is delayed to an older age. There may be linkage disequilibrium between p.Arg117His and 12 TG repeats. European Respiratory Society 2017-03-31 /pmc/articles/PMC5566269/ /pubmed/28845426 http://dx.doi.org/10.1183/23120541.00056-2016 Text en Copyright ©ERS 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0.
spellingShingle Original Articles
Shteinberg, Michal
Downey, Damian G.
Beattie, Diane
McCaughan, John
Reid, Alastair
Stein, Nili
Elborn, J. Stuart
Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title_full Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title_fullStr Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title_full_unstemmed Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title_short Lung function and disease severity in cystic fibrosis patients heterozygous for p.Arg117His
title_sort lung function and disease severity in cystic fibrosis patients heterozygous for p.arg117his
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5566269/
https://www.ncbi.nlm.nih.gov/pubmed/28845426
http://dx.doi.org/10.1183/23120541.00056-2016
work_keys_str_mv AT shteinbergmichal lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT downeydamiang lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT beattiediane lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT mccaughanjohn lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT reidalastair lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT steinnili lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his
AT elbornjstuart lungfunctionanddiseaseseverityincysticfibrosispatientsheterozygousforparg117his